Back
13 Apr 2026
Singapore-listed IX Biopharma bets big on non-opioid pain relief
[SINGAPORE] It took semaglutide (an anti-diabetic prescription drug that is gaining traction as an anti-obesity medication) to convince Wall Street that an overlooked drug class could become a hundred-billion-dollar market. Now, a handful of companies are betting that non-opioid pain relief is next – and Singapore’s IX BioPharma : 42C +65% thinks it has the edge.
The company’s flagship drug, Wafermine, is a sublingual ketamine wafer designed to dissolve under the tongue and deliver rapid pain relief without the addiction risks that have made opioids so controversial.